DoctorLauren Akesson

(she/her)

Clinical Senior Research Fellow

Menzies Institute for Medical Research

  • Clinical Senior Research Fellow
    Menzies Institute for Medical Research

RESEARCH SUMMARy

Dr Akesson's main research interest is improving access to genetic and rare disease healthcare for all Australians, especially those living in rural areas. She is conducting a study (CLEAR Consent Study) to determine whether an Easy English, Rural-informed Adaptation of Genetics Adviser (an online education and consent tool) improves access to genetic testing for people who might have hereditary cancer. She is also supervising an Honours student who is examining barriers and enablers of a Nurse Navigator role in rare disease in rural areas. 

FUNDED PROJECTS

  • GRANT
    Genetics Adviser: A Digital Health Intervention to Increase Genetic Testing Uptake in Rural lutruwita/Tasmania
    1 Oct 2025 - 30 Apr 2027
    People funded by this grant:
    • Akesson L,
    • Wallis M,
    • Pope-Couston R,
    • Dickinson J,
    • Raspin K
    Project Total: $72,727; Precision medicine represents an opportunity to make a difference in the lives of families and individuals with hereditary cancer and rare disease. However, not everyone who could potentially benefit from precision medicine are undergoing genetic testing, resulting in inequitable access. Vulnerable populations, including those from rural areas, are at increased risk of this inequity. The overarching aim of this research is to implement a digital health intervention (DHI) (Genetics Adviser) to increase the number of rural Tasmanians that benefit from genetic testing, opening the door to precision medicine. Objectives: Determine the informational needs of rural Tasmanians affected by hereditary cancer or rare diseaseCo-design adaptations to a validated DHI according to the informational needs analysisConduct a Randomised Controlled Trial using a mixed methods approach The goal of this research is to ensure that all Tasmanians with a genetic condition have an opportunity to benefit from precision medicine: targeted therapies and/or clinical trials, and family-based testing of at-risk relatives, which will help improve health outcomes. Evaluation of Genetics Adviser in a rural Tasmanian population will provide information about whether using Genetics Adviser as a decisional aid increases genetic testing uptake, thus increasing the potential for precision medicine; or makes the process of choosing whether to have genetic testing more satisfying. Comparing genetic testing uptake in rural and urban communities will increase the evidence for digital health interventions in the rural setting, as a tool to increase equitable access for genetic testing and precision medicine in all Tasmanians. Funded by: Clifford Craig Foundation - Grant-Research ($72,695); University of Tasmania ($5,261).
  • GRANT
    Genetics Adviser: A Digital Health Intervention to Increase Genetic Testing Uptake for Hereditary Cancer in Rural lutruwita/Tasmania
    1 Jan 2025 - 30 Sep 2026
    People funded by this grant:
    • Akesson L,
    • Wallis M,
    • Pope-Couston R,
    • Dickinson J,
    • Raspin K
    Project Total: $39,955; Rationale The overall aim of this research project is to increase genetic testing uptake for hereditary cancer in rural lutruwita/Tasmania. We propose to do this through a Digital Health intervention (Genetics Adviser), focussing on consumer education in conjunction with a streamlined eConsent pathway within existing mainstreaming and telehealth models. By increasing the uptake of genetic testing, the capacity for personalised medicine is realised, including targeted therapies, screening for at-risk cancers, and counselling and interventions for relatives who may have the same genetic condition. As genetic counselling for hereditary cancer genetic testing is distinct, compared to counselling for rare disease, generic genetic counselling tools designed for rare disease may not be directly transferable to hereditary cancer. Vision Our vision is to adapt an existing Digital Health innovation (Genetics Adviser), containing information required to make an informed decision or choice about genetic testing, and offer this to a rural population of individuals undergoing hereditary cancer genetic testing in lutruwita/Tasmania, increasing genetic testing uptake and participant satisfaction. Aims: to determine what rural (Launceston and surrounds) and urban (Hobart) individuals with hereditary cancer[1], treating clinicians (oncologists, surgeons) and consumer advocates wish to see in a Digital Health intervention (qualitative research using semi-structured interviews and a Delphi technique).to adapt an existing Digital Health intervention (Genetics Adviser) to end-user preferences.to conduct a Randomised Controlled Trial situated in Launceston and Hobart, comparing Genetics Adviser to current standard of care. Hypothesis We hypothesise that a Digital Health intervention will: increase uptake of genetic testing improve participant satisfaction with the genetic testing process. Potential outcomes Increased uptake of genetic testing has the potential to underpin personalised medicine, thereby enhancing capacity to demonstrate eligibility for targeted therapies; prevention and screening for second cancers; and referral of at-risk relatives to genetic services. [1] Hereditary cancers to be included in this trial are Hereditary Breast Ovarian Cancer (breast, ovarian, pancreatic) and suspected Lynch syndrome (colorectal, endometrial cancer with MMR deficiency on histology) Funded by: Cancer Council of Tasmania - Grant - Small Grant Program ($39,955); University of Tasmania.
  • GRANT
    Genetics Adviser: A Digital Health Intervention to Increase Genetic Testing Uptake in Rural lutruwita/Tasmania
    1 Jan 2025 - 31 Dec 2026
    People funded by this grant:
    • Akesson L,
    • Wallis M,
    • Pope-Couston R,
    • Dickinson J,
    • Raspin K
    Project Total: $53,000; The overarching goal of this research is to adapt and implement an existing Digital Health Intervention, Genetics Adviser, to enhance patient satisfaction of the genetic testing process and increase access to genetic testing for Rural Tasmanians, resulting in increased genetic testing uptake. This research will be conducted in rural lutruwita/Tasmania to ensure benefits are applicable to all Tasmanians. Ultimately, we anticipate that more Tasmanians will be able to access personalised medicine because of this research. Outline of the Research: The research will be conducted in three phases. Phase One: Determine the informational needs of individuals and families affected by hereditary cancer and/or rare disease. This phase will consist of qualitative research, starting with semi-structured interviews with prior participants of genetic healthcare, gaining information about their experience with the current Standard of Care model. As part of this process, they will be shown Genetics Adviser and asked to comment on which aspects are most beneficial and which aspects could be improved. This will be followed by a Delphi process which will be conducted with healthcare professionals and consumer advocates, with questions informed by the semi-structured interviews. Phase Two: Adapt Genetics Adviser. Following data analysis and interpretation from Phase One, the second phase of the research will be targeted interviews with the developers of Genetics Adviser to design, evaluate, plan, and implement the adaptations derived from the first phase. Phase Three: Conduct a Randomised Controlled Trial. The primary outcome of this trial will be genetic testing uptake, and the secondary outcome will be participant satisfaction. In the RCT, the Standard of Care arm will receive standard genetic counselling for genetic testing, while the Active arm will receive genetic counselling augmented with the adapted Genetics Adviser. The groups will be stratified by hereditary cancer vs rare disease; gender; and site (urban vs rural). Funded by: The MPST Foundation Ltd - Grant-Medical Protection Society of Tasmania Foundation Grant ($52,999); University of Tasmania.